<DOC>
	<DOCNO>NCT00539877</DOCNO>
	<brief_summary>Stomach cancer common cancer , still lead cause death Korea . Peritoneal seed common metastasis gastric cancer , frequent cause death disease . In addition , standard treatment peritoneal dissemination . Even though systemic intravenous chemotherapy standard treatment metastatic stomach cancer present , improve survival patient peritoneal dissemination . Because intraperitoneal ( IP ) administration result high concentration locally low systemic toxicity , clinical investigator confirm safety pharmacokinetic advantage associate IP delivery number antineoplastic agent know activity cancer . In ovarian cancer , large randomize trial demonstrate small statistically clinically significant survival advantage woman receive portion therapy intraperitoneally . Drugs 5-fluorouracil , cisplatin , mitomycin-C , paclitaxel docetaxel use IP chemotherapy patient gastric cancer . Even small number phase III trial report , study show improvement survival patient randomize IP therapy compare receive postoperative treatment . Irinotecan ( 7-ethyl-10- [ 4- ( 1-pipperidino ) -1-piperidino ] carbonyloxy camptothecin ; CPT-11 ) , clinically effective treatment colorectal , lung gastric cancer , carbamate prodrug metabolize active metabolite , 7-ethyl-10-hydroxycamptothecin ( SN-38 ) . In mouse model , IP administration CPT-11 significantly effective intravenous administration control peritoneal seed liver metastasis . However , phamacokinetics CPT-11 peritoneal administration human being well study . Although Japanese investigator report pharmacokinetic data CPT-11 patient , data maximum tolerate dose CPT-11 intraperitoneally .</brief_summary>
	<brief_title>Phase I Study Interperitoneal Chenotherapy Patients With Gastric Adenocarainoma With Peritoneal Seeding</brief_title>
	<detailed_description>Objectives : The objective study assess feasibility , determine maximum tolerate dose , assess toxicity intraperitoneally administer CPT-11 gastric cancer patient peritoneal seed . Methods : This open-labeled , non-randomized phase I study patient eligible follow criterion . Patients 18 year old gastric adenocarcinoma , histologically proven , enrol time surgery , sign informed consent obtain prior surgery . Preoperative study resectable advanced disease . The operative finding biopsy suspect peritoneum must show peritoneal involvement adenocarcinoma . The subject previous chemotherapy , immunotherapy radiotherapy major biological abnormality . Prior initiation study , patient receive palliative gastrectomy ( total subtotal ) CAPD catheter . Postoperative day 1 , IP chemotherapy give CAPD catheter . For dose level 1 , CPT-11 ( provide CJ Pharmaceutical Company ) 50mg/m2 1L normal saline , prewarmed 37°C give intraperitoneally . Plasma sample collect prior IP chemotherapy , sample plasma , peritoneal fluid urine obtain 0.5 , 1.5 , 2 , 3.5 , 8 , 12 , 25.5 , 49 , 56 hour follow chemotherapy . Three patient accrue dose level . If none three patient experience dose-limiting toxicity ( DLT ) , dose increased subsequent group three patient 100 mg/m2.If one first three patient experience DLT , three patient accrue dose level . If none additional three patient experience DLT , dose escalate . If one additional three patient experience DLT , either additional cohort patient could add escalation terminate . If two second group three patient experience DLT , accrual stop . If two first three patient experience DLT , additional three patient could accrue dose level , dose escalation could take place none additional cohort experience DLT . The last plan dose escalation 300 mg/m2 . Cohorts least 3 patient enter dose level monitor least 4 week treatment dose escalation . Intrapatient dose escalation permit . Dose level Dose IP CPT-11 ( mg/m2 ) 1 . 50 2 . 100 3 . 150 4 . 200 5 . 300 In study , DLT define follow : grade 4 non-hematologic toxicity note ; ≥ grade 3 diarrhea stomatitis last ≥ 7 day despite optimal supportive care ; hematologic dose-limiting toxicity define grade 4 neutropenia complicate fever ≥ 38°C ; grade 4 hemorrhage thrombocytopenia ; failure recover neutrophil ( ≥ 1500/ mm3 ) platelet ( ≥ 100 000/ mm3 ) day 28 . The maximal tolerate dose define dose level produce dose-limiting toxicity ≥ 50 % patient . The recommend dose one level . During study , evaluation toxicity do daily postoperative 6 day weekly use National Cancer Institute-Common Toxicity Criteria ( NCI-CTC ) . Physical examination , complete blood count , blood chemistry , serum electrolyte measure . Pharmacokinetic study : Plasma , peritoneal fluid urine sample assay irinotecan metabolite : SN-38 , 7-ethyl-10- [ 4-N- ( 5-aminopentanoic acid ) -1-piperidino ] carbonyl camptothecin ( APC ) , SN-38 glucuronide ( SN-38G ) .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Patients eligible follow criterion meet ; Histologic diagnosis gastric adenocarcinoma Preoperative study resectable disease ; endoscopic find advanced gastric cancer , radiologic find T3 T4 disease without suspicious peritoneal seed Males female least 18 year age Performance status 01 ECOG criteria The operative finding biopsy suspect peritoneum must show peritoneal involvement adenocarcinoma No previous chemotherapy , immunotherapy radiotherapy No biological major abnormality . Adequate hematologic ( WBC count ≥ 4,000/mm3 , platelet count ≥ 150,000/mm3 ) , hepatic ( bilirubin level £ 1.5 mg/dL ) , renal ( creatinine concentration £ 1.5 mg/dL ) function . Informed consent patient patient 's relative If female : childbearing potential either terminate surgery , radiation , menopause , attenuate use approve contraceptive method ( intrauterine device [ IUD ] , birth control pill , barrier device ) 3 month trial . If male , use approve contraceptive method study 3 month afterwards Myocardial infarction within precede 6 month symptomatic heart disease , include unstable angina , congestive heart failure uncontrolled arrhythmia Serious concomitant infection Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin prior malignancy treat 5 year ago without recurrence ) History significant neurologic psychiatric disorder Pregnant lactate woman Women child bear potential use contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Gstric cancer</keyword>
	<keyword>Pritoneal seed</keyword>
	<keyword>Intraperitoneal chemotherapy</keyword>
	<keyword>Irinotecan</keyword>
</DOC>